124 related articles for article (PubMed ID: 22825460)
1. Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer.
Rodríguez Faba O; Palou J
Curr Opin Urol; 2012 Sep; 22(5):415-20. PubMed ID: 22825460
[TBL] [Abstract][Full Text] [Related]
2. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
3. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
4. Current management of non-muscle-invasive bladder cancer.
Rodriguez Faba O; Gaya JM; López JM; Capell M; De Gracia-Nieto AE; Gómez Correa E; Breda A; Palou J
Minerva Med; 2013 Jun; 104(3):273-86. PubMed ID: 23748281
[TBL] [Abstract][Full Text] [Related]
5. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
6. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
[TBL] [Abstract][Full Text] [Related]
7. [Muscularis mucosae invasion: prognostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma].
Nguyen-Huu Y; Delorme G; Lillaz J; Bedgedjian I; Le Ray-Ferrières I; Chabannes E; Bernardini S; Guichard G; Bittard H; Kleinclauss F
Prog Urol; 2012 May; 22(5):284-90. PubMed ID: 22515925
[TBL] [Abstract][Full Text] [Related]
8. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
9. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.
Kulkarni GS; Hakenberg OW; Gschwend JE; Thalmann G; Kassouf W; Kamat A; Zlotta A
Eur Urol; 2010 Jan; 57(1):60-70. PubMed ID: 19740595
[TBL] [Abstract][Full Text] [Related]
10. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
11. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
12. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
13. High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.
Faba OR; Palou J; Breda A; Villavicencio H
World J Urol; 2012 Dec; 30(6):833-40. PubMed ID: 23070534
[TBL] [Abstract][Full Text] [Related]
14. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
15. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?
Segal R; Yafi FA; Brimo F; Tanguay S; Aprikian A; Kassouf W
BJU Int; 2012 Apr; 109(7):1026-30. PubMed ID: 21883838
[TBL] [Abstract][Full Text] [Related]
17. Contemporary management of stage T1 transitional cell carcinoma of the bladder.
Soloway MS; Sofer M; Vaidya A
J Urol; 2002 Apr; 167(4):1573-83. PubMed ID: 11912367
[TBL] [Abstract][Full Text] [Related]
18. Strategies to prevent progression of high-risk bladder cancer at initial diagnosis.
Ku JH; Lerner SP
Curr Opin Urol; 2012 Sep; 22(5):405-14. PubMed ID: 22842680
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
20. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
